Position in TRVI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$19,620,601
New position
Shares Held
1,052,043
first reported quarter
Ownership
0.738%
of shares outstanding
% of Portfolio
2.81%
of 13F equity value
Holder Rank
#40
of 216 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Saturn V Capital Management LP holds $614,415,149 across 22 Biotechnology names. TRVI ranks #13 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALMS |
Alumis Inc.
|
2,915,443 | $82,040,566 | |
| 2 | ABVX |
Abivax S.A.
|
518,865 | $69,143,949 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
852,914 | $49,579,890 | |
| 4 | IMMX |
Immix Biopharma, Inc.
|
4,658,429 | $48,028,402 | |
| 5 | PHVS |
Pharvaris N.V.
|
1,314,122 | $45,442,338 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
160,938 | $38,781,229 | |
| 7 | CELC |
Celcuity Inc.
|
370,318 | $38,742,669 | |
| 8 | IRON |
Disc Medicine, Inc.
|
524,730 | $38,378,752 |
All Filings in TRVI
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19,620,601 | 1,052,043 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||